Novo Nordisk A/S (NVO)
125.80
-0.36
(-0.29%)
USD |
NYSE |
Apr 25, 16:00
125.74
-0.06
(-0.05%)
After-Hours: 16:51
Novo Nordisk Net Income (Quarterly): 3.170B for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.170B |
| September 30, 2023 | 3.283B |
| June 30, 2023 | 2.839B |
| March 31, 2023 | 2.857B |
| December 31, 2022 | 1.868B |
| September 30, 2022 | 1.950B |
| June 30, 2022 | 1.907B |
| March 31, 2022 | 2.144B |
| December 31, 2021 | 1.675B |
| September 30, 2021 | 1.921B |
| June 30, 2021 | 1.965B |
| March 31, 2021 | 2.046B |
| December 31, 2020 | 1.493B |
| September 30, 2020 | 1.618B |
| June 30, 2020 | 1.569B |
| March 31, 2020 | 1.756B |
| December 31, 2019 | 1.292B |
| September 30, 2019 | 1.519B |
| June 30, 2019 | 1.444B |
| March 31, 2019 | 1.590B |
| December 31, 2018 | 1.299B |
| September 30, 2018 | 1.409B |
| June 30, 2018 | 1.657B |
| March 31, 2018 | 1.774B |
| December 31, 2017 | 1.306B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.544B |
| June 30, 2017 | 1.471B |
| March 31, 2017 | 1.455B |
| December 31, 2016 | 1.261B |
| September 30, 2016 | 1.470B |
| June 30, 2016 | 1.513B |
| March 31, 2016 | 1.398B |
| December 31, 2015 | 1.211B |
| September 30, 2015 | 1.248B |
| June 30, 2015 | 1.235B |
| March 31, 2015 | 1.496B |
| December 31, 2014 | 1.096B |
| September 30, 2014 | 1.156B |
| June 30, 2014 | 1.285B |
| March 31, 2014 | 1.186B |
| December 31, 2013 | 1.105B |
| September 30, 2013 | 1.140B |
| June 30, 2013 | 1.180B |
| March 31, 2013 | 1.059B |
| December 31, 2012 | 1.001B |
| September 30, 2012 | 951.38M |
| June 30, 2012 | 923.11M |
| March 31, 2012 | 822.39M |
| December 31, 2011 | 849.02M |
| September 30, 2011 | 796.82M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
1.292B
Minimum
Dec 2019
3.283B
Maximum
Sep 2023
2.017B
Average
1.907B
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Amgen Inc | 767.00M |
| AstraZeneca PLC | 960.00M |
| Sanofi SA | -597.68M |
| Viking Therapeutics Inc | -24.60M |
| Evaxion Biotech AS | -4.523M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.505B |
| Total Expenses (Quarterly) | 5.643B |
| EPS Diluted (Quarterly) | 0.7086 |
| Enterprise Value | 561.51B |
| Gross Profit Margin (Quarterly) | 84.80% |
| Profit Margin (Quarterly) | 33.35% |
| Earnings Yield | 2.15% |
| Operating Earnings Yield | 2.63% |
| Normalized Earnings Yield | 2.148 |